Literature DB >> 22157809

Long-term WT1 peptide vaccination for patients with acute myeloid leukemia with minimal residual disease.

A Tsuboi, Y Oka, T Kyo, Y Katayama, O A Elisseeva, M Kawakami, S Nishida, S Morimoto, A Murao, H Nakajima, N Hosen, Y Oji, H Sugiyama.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22157809     DOI： 10.1038/leu.2011.343

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  24 in total

1.  Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: part II. Autologous Transplantation-novel agents and immunomodulatory strategies.

Authors:  David Avigan; Parameswaran Hari; Minoo Battiwalla; Michael R Bishop; Sergio A Giralt; Nancy M Hardy; Nicolaus Kröger; Alan S Wayne; Katharine C Hsu
Journal:  Biol Blood Marrow Transplant       Date:  2013-09-07       Impact factor: 5.742

Review 2.  Wilms tumor 1 peptide vaccination after hematopoietic stem cell transplant in leukemia patients.

Authors:  Naoki Hosen; Tetsuo Maeda; Yoshiko Hashii; Akihiro Tsuboi; Sumiyuki Nishida; Jun Nakata; Yusuke Oji; Yoshihiro Oka; Haruo Sugiyama
Journal:  Stem Cell Investig       Date:  2016-12-09

3.  An immunogenic WT1-derived peptide that induces T cell response in the context of HLA-A*02:01 and HLA-A*24:02 molecules.

Authors:  Tao Dao; Tatyana Korontsvit; Victoria Zakhaleva; Casey Jarvis; Patrizia Mondello; Claire Oh; David A Scheinberg
Journal:  Oncoimmunology       Date:  2016-12-07       Impact factor: 8.110

Review 4.  Life after transplant: are we becoming high maintenance in AML?

Authors:  A M Brunner; A T Fathi; Y B Chen
Journal:  Bone Marrow Transplant       Date:  2016-06-20       Impact factor: 5.483

5.  Identification of molecular and cytogenetic risk factors for unfavorable core-binding factor-positive adult AML with post-remission treatment outcome analysis including transplantation.

Authors:  J-H Yoon; H-J Kim; J-W Kim; Y-W Jeon; S-H Shin; S-E Lee; B-S Cho; K-S Eom; Y-J Kim; S Lee; C-K Min; S-G Cho; J-W Lee; W-S Min; C-W Park
Journal:  Bone Marrow Transplant       Date:  2014-08-11       Impact factor: 5.483

Review 6.  Cancer immune therapy for myeloid malignancies: present and future.

Authors:  Morten Orebo Holmström; Hans Carl Hasselbalch
Journal:  Semin Immunopathol       Date:  2018-07-09       Impact factor: 9.623

7.  Calreticulin is an effective immunologic adjuvant to tumor-associated antigens.

Authors:  Jun Wang; Zhi Peng Gao; Song Qin; Chang Bai Liu; Li Li Zou
Journal:  Exp Ther Med       Date:  2017-08-22       Impact factor: 2.447

8.  Therapeutic vaccination against leukaemia via the sustained release of co-encapsulated anti-PD-1 and a leukaemia-associated antigen.

Authors:  Xiaoling Xie; Yuxing Hu; Tong Ye; Yiran Chen; Lijuan Zhou; Feng Li; Xiaobo Xi; Shuang Wang; Yanjie He; Xiaoyong Gao; Wei Wei; Guanghui Ma; Yuhua Li
Journal:  Nat Biomed Eng       Date:  2020-10-12       Impact factor: 25.671

Review 9.  Wilms tumor 1 mutations in the pathogenesis of acute myeloid leukemia.

Authors:  Raajit Rampal; Maria E Figueroa
Journal:  Haematologica       Date:  2016-06       Impact factor: 9.941

10.  The key role of calreticulin in immunomodulation induced by chemotherapeutic agents.

Authors:  Yoshiyuki Yamamura; Takahiro Tsuchikawa; Kengo Miyauchi; Shintaro Takeuchi; Masataka Wada; Toshihiko Kuwatani; Noriaki Kyogoku; Aki Kuroda; Takehiro Maki; Toshiaki Shichinohe; Satoshi Hirano
Journal:  Int J Clin Oncol       Date:  2014-06-28       Impact factor: 3.402
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.